Tai Feipeng, Zhao Xueming
First Clinical Medical College, Shanxi Medical University, Taiyuan, China.
The First Hospital of Shanxi Medical University, Taiyuan, China.
Cell Mol Biol (Noisy-le-grand). 2024 May 27;70(5):233-237. doi: 10.14715/cmb/2024.70.5.34.
This review aimed to comprehensively summarize the role of long non-coding RNA (lncRNA) in gliomas, the most common malignant tumors in the central nervous system, and explore their potential clinical applications. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search using the PubMed database was conducted forty studies met the inclusion and exclusion criteria and were analyzed for type of intervention, the study's design, participants' demographics, and outcomes, including attrition. Gliomas, originating within the central nervous system, account for 40-45% of intracranial tumors. Despite advances in neurosurgical techniques, precise radiotherapy, and chemotherapy, the prognosis for glioma patients remains suboptimal. The review highlights the crucial regulatory role of lncRNA in gliomas. Differential expression of various lncRNAs, such as INHEG, SATB2-AS1, PSMB8-AS1, LINC01018, and SPRY4-IT1, has been observed in gliomas, suggesting their involvement in promoting or inhibiting tumorigenesis. Additionally, lncRNAs play roles in glioma characteristics such as proliferation, invasion, migration, angiogenesis, and the presence of glioma stem cells. The potential clinical applications of lncRNA in gliomas involve their association with tumor grading, diameter, metastasis, and family history. This review emphasizes the importance of understanding the molecular mechanisms involving lncRNA in gliomas. The identification of specific lncRNAs associated with gliomas provides potential molecular markers for diagnosis, differentiation, treatment, and prognosis evaluation. Further research is needed to uncover additional key lncRNAs and their underlying mechanisms, ultimately contributing to the improvement of glioma diagnosis and treatment.
本综述旨在全面总结长链非编码RNA（lncRNA）在胶质瘤（中枢神经系统最常见的恶性肿瘤）中的作用，并探索其潜在的临床应用。按照系统评价和Meta分析的首选报告项目（PRISMA）指南，使用PubMed数据库进行了系统检索。40项研究符合纳入和排除标准，并对干预类型、研究设计、参与者的人口统计学特征以及结果（包括损耗情况）进行了分析。胶质瘤起源于中枢神经系统，占颅内肿瘤的40%-45%。尽管神经外科技术、精确放疗和化疗取得了进展，但胶质瘤患者的预后仍然不尽人意。该综述强调了lncRNA在胶质瘤中的关键调节作用。在胶质瘤中观察到多种lncRNA的差异表达，如INHEG、SATB2-AS1、PSMB8-AS1、LINC01018和SPRY4-IT1，提示它们参与促进或抑制肿瘤发生。此外，lncRNA在胶质瘤的增殖、侵袭、迁移、血管生成以及胶质瘤干细胞的存在等特征方面发挥作用。lncRNA在胶质瘤中的潜在临床应用涉及其与肿瘤分级、直径、转移和家族史的关联。本综述强调了理解胶质瘤中涉及lncRNA的分子机制的重要性。鉴定与胶质瘤相关的特定lncRNA可为诊断、鉴别、治疗和预后评估提供潜在的分子标志物。需要进一步研究以发现更多关键的lncRNA及其潜在机制，最终有助于改善胶质瘤的诊断和治疗。
